What are Key Considerations When Launching a Rare Disease Drug in a Specialty-Naive Market?
February 28th 2018Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, speaks about the many considerations that have to be addressed when launching a novel rare disease drug in a specialty-naive market.